No evidence of benefit for Chloroquine and Hydroxychloroquine in COVID-19 patients, study finds
A large observational study suggests that treatment with the antimalarial drug chloroquine or its analogue hydroxychloroquine (taken with or without the antibiotics azithromycin or clarithromycin) offers no benefit for patients with COVID-19. The study analysed data from nearly 15,000 patients with COVID-19 receiving a combination of any of the four drug regimens and 81,000 controls.
Treatment with these medications among patients with COVID-19, either alone or in combination with macrolide antibiotics, was linked to an increased risk of serious heart rhythm complications in these patients.
Researchers suggest these treatment regimens should not be used to treat COVID-19 outside of clinical trials until results from randomised clinical trials are available to confirm the safety and efficacy of these medications for COVID-19 patients.
For more details: https://pharmacology.healthconferences.org/
E-mail: pharmafroum@theexpertsmeet.com
Contact: +447426056247
E-mail: pharmafroum@theexpertsmeet.com
Contact: +447426056247
No comments:
Post a Comment